Passionate about Progress

We are developing nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

Nalbuphine ER is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options.

Nalbuphine has a dual mechanism of action, acting as both an antagonist (blocker) to the body’s mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. The kappa and mu opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with mu opioid agonists because it blocks the mu opioid receptor. Nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe.

We are developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal Phase 2b/3 clinical trial of nalbuphine ER (PRISM) is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). In addition, we are preparing to initiate a Phase 2 clinical trial of nalbuphine ER for the treatment of chronic cough in patients with IPF and a Phase 2 clinical trial of nalbuphine ER for the treatment of LID in patients with Parkinson’s disease.

Founded in 2011, Trevi Therapeutics is headquartered and proud to be part of the vibrant life science community in New Haven, CT.

leadership

Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value.

Management Team

Jennifer Good

Co-Founder,
President and CEO

Thomas Sciascia, M.D.

Co-Founder,
Chief Medical Officer

Helena Brett-Smith, M.D.

Chief Development Officer

Yann Mazabraud

Chief Commercial Officer
and Head of International

Christopher J. Seiter

Chief Financial Officer

Board of Directors

David Meeker, M.D. – Chairman
David Meeker, M.D. has served as a member of our board of directors and our chairman since July 2017. Dr. Meeker has served as Chief Executive Officer and director of KSQ Therapeutics, Inc., a biotechnology company, since September 2017. Prior to joining KSQ, Dr. Meeker worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including as president and chief executive officer of Genzyme from October 2011 until June 2017, as a member of Sanofi’s Executive Committee from 2012 to June 2017 and as executive vice president and head of Sanofi Genzyme, Sanofi’s specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation, beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as chief operating officer. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr. Meeker has served as a director of Rhythm Pharmaceuticals, Inc. since November 2015 and as its chairman of the board since April 2017. Dr. Meeker has also served as a director of MyoKardia, Inc. since April 2017. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. He completed his internal medicine training at Harvard University’s Beth Israel Hospital and pulmonary/critical care training at Boston University.
Mette Kirstine Agger
Mette Kirstine Agger has served as a member of our board of directors since July 2017. Since 2009, Ms. Agger has served as a managing partner of Lundbeckfonden Ventures, a life science venture fund. Prior to joining Lundbeckfonden Ventures, Ms. Agger co-founded 7TM Pharma A/S, a biotech company engaged in therapeutic drug discovery and development, in 2000, and served as its chief executive officer from founding to 2009. Prior to founding 7TM Pharma, Ms. Agger was part of the management team of NeuroSearch A/S, a drug research and development company. Ms. Agger serves on numerous boards of private and public companies. She has served on the board of scPharmaceuticals Inc. since March 2014, and on the board of Veloxis Pharmaceuticals A/S since April 2010. She also serves on the board of Klifo A/S, a pharmaceutical consulting company, Cydan Development, Inc., an orphan drug startup accelerator, Imara Inc., a drug company, PsiOxus Therapeutics, Ltd., a biopharmaceutical company, and Thesan Pharmaceuticals, Inc., a biopharmaceutical company. Ms. Agger graduated with an M.Sc. in biology from the University of Copenhagen and received an M.B.A. from Henley Business School University of Reading.
Jennifer Good
Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. While at Penwest, she led the transition of the publicly traded life sciences company from development stage to generating annual revenues in excess of $50 million. The company was acquired by its strategic partner in 2010. Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. Ms. Good has also served as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, since 2011. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.
Michael Heffernan
Michael Heffernan has served on our board of directors since February 2017. Mr. Heffernan served as the president, chief executive officer and director of Collegium Pharmaceutical, Inc., a publicly traded pharmaceutical company, from October 2002 until July 2018, at which time he transitioned to the role of chairman of the board of directors. He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its president and chief executive officer from 2005 to 2010. Mr. Heffernan previously founded and served as president and chief executive officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., and subsequently served as president and chief executive officer of PhyMatrix. Mr. Heffernan started his career at Eli Lilly and Company, where he held numerous sales and marketing roles. Mr. Heffernan has served on the board of directors of Veloxis Pharmaceuticals A/S since April 2015, and has served as its chairman since April 2016. Mr. Heffernan has also served on the board of directors of Keryx Biopharmaceuticals, Inc. since April 2016. Mr. Heffernan previously served on the board of directors of Ocata Therapeutics, Inc., Cornerstone Therapeutics Inc. (now known as Chiesi USA, Inc.), and several privately held companies. Mr. Heffernan graduated from the University of Connecticut with a B.S. in pharmacy in 1987 and is a registered pharmacist.
Ed Mathers
Edward Mathers has served on our board of directors since July 2017. Mr. Mathers has been a partner at New Enterprise Associates, Inc., a private venture capital firm, since August 2008. Mr. Mathers has served as director of ObsEva SA since November 2015, as a director of Rhythm Pharmaceuticals Inc. since March 2013, as a director of Ra Pharmaceuticals, Inc. since 2010, as a director of Liquidia Technologies, Inc. since 2009, and as a director of Synlogic, Inc. since October 2012. He is also on the board of a number of private life sciences companies. Mr. Mathers earned his B.S. in chemistry from North Carolina State University.
Annie Mitsak, Ph.D.
Annie Mitsak, Ph.D. has served on our board of directors since August 2018. Ms. Mitsak is a senior associate at Omega Fund Management, LLC, a private venture capital firm, where she has worked since October 2015. Prior to joining Omega, Ms. Mitsak worked at the Technology Licensing Office at the Massachusetts Institute of Technology from 2012 to October 2015 as an associate licensing officer, where she managed a portfolio of drug delivery and biotechnology inventions. Ms. Mitsak also worked as an independent consultant for Nelsen Biomedical from January 2015 to October 2015. Ms. Mitsak earned her B.S. in biomedical engineering from the University of Virginia and earned her Ph.D. in biomedical engineering from the University of Michigan.
Eran Nadav, Ph.D.
Dr. Eran Nadav is an investor and a biopharma veteran. He has been with the investment firm TPG from 2007 to 2018, serving as Partner and Managing Director at the TPG Biotech fund in San Francisco. During his tenure at TPG, he led pharma and biotech deals across various geographies and stages of development. Currently he serves as Senior Advisor of TPG Biotech.

Prior to TPG, Dr. Nadav was Business Development Director at Eisai in New Jersey, where he evaluated and negotiated licensing and acquisition deals. Previously, Dr. Nadav worked for JJDC, the venture capital subsidiary of Johnson & Johnson. Earlier, he worked for Neurim Pharmaceuticals in a product development role.

Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA from Tel Aviv University.

Dr. Nadav is currently a board member at Carisma Therapeutics, Fusion Pharmaceuticals, Trevi Therapeutics, and Tevel Aerobotics Technologies. He is also a member at the Investment Committee at Lagunita Biosciences, a healthcare investment company and incubator. Dr. Nadav was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics. His other past investments and board roles include Collegium Pharmaceutical (Nasdaq: COLL), JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), ShangPharma (a China based CRO), and Eden Springs / Mey Eden (a leading European provider of workplace drinks solutions).

Anne VanLent
Anne VanLent has served on our board of directors since October 2018. Since May 2008, Ms. VanLent has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. from 2002 through 2008. From 1997 to 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a biopharmaceutical company that was acquired by Elan Corp. plc. Ms. VanLent has served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation since August 2016. Since May 2013, Ms. VanLent has also served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.). During the past five years, Ms. VanLent served as a director of Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt plc, from 2011 to December 2017; Novelion Pharmaceuticals Inc. (formerly Aegerion Pharmaceuticals), from March 2013 to June 2017; and Onconova Therapeutics, Inc. from June 2013 to May 2016. Ms. VanLent received a B.A. degree in physics from Mount Holyoke College.